Nectar Lifesciences Ltd
NECLIFE (NSE)

23.20

520.29
Proj. ROE (%)
-
Proj. P/E (x)
-
Proj EV / EBITDA (x)
-
Proj. P/BV (x)
-
Proj. Revenue ( Cr.)
-

Stock View

-
Share on
The average score for Nectar Lifesciences Ltd stands at 4 against 2, three months back.

Nectar Lifesciences Limited is an India-based integrated pharmaceutical organization. The Company has developed fully integrated sustainable production systems to manufacture cephalosporin intermediates, active pharmaceuticals ingredients (APIs) and finished dosage formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and approximately 75 countries worldwide. The Company operates only in the business segment of Pharmaceuticals Products. The Company’s products include Cefixime, Cefuroxime Axetil, Ceftriaxone Sodium, and Menthol and its derivatives. The Company’s subsidiaries include Nectar Lifesciences USA, LLC; Nectar Lifesciences UK Limited, United Kingdom and Neclife PT, Unipessoal LDA, Portugal.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
25.41
100 DMA ()
27.00
200 DMA ()
27.81
52 Weeks Range
20.75
47.90
Street View :-
Bearish
Open ZERO Brokerage Demat Account
Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity